Live feed12:00:00·3hPRReleasevia QuantisnowNew First-in-Class Therapy for Chronic Graft-Versus-Host Disease Approved in Australia[1]ByQuantisnow·Wall Street's wire, on your screen.INCY· Incyte Corp.Health Care
